

Annex to press release 8 October 2020 - Preliminary comparative figures

| amounts in €m | 2019 | | | | | 2020 | |
|-----------------------------|-------|-------|-------|-------|-------|-------|-------|
| | Q1 | Q2 | Q3 | Q4 | year | Q1 | Q2 |
| Nutrition | | | | | | | |
| Sales | 1,517 | 1,512 | 1,544 | 1,455 | 6,028 | 1575 | 1649 |
| Adj. EBITDA | 316 | 323 | 317 | 294 | 1,250 | 324 | 350 |
| Adj. EBIT | 228 | 234 | 225 | 194 | 881 | 229 | 249 |
| Materials | | | | | | | |
| Sales | 449 | 443 | 435 | 417 | 1,744 | 413 | 317 |
| Adj. EBITDA | 91 | 97 | 90 | 94 | 372 | 85 | 40 |
| Adj. EBIT | 67 | 72 | 65 | 66 | 270 | 60 | 15 |
| Innovation Center | | | | | | | |
| Sales | 44 | 42 | 47 | 51 | 184 | 47 | 44 |
| Adj. EBITDA | 6 | 7 | 6 | 7 | 26 | 5 | 6 |
| Adj. EBIT | 0 | -3 | -4 | -5 | -12 | -4 | -5 |
| Corporate Activities | | | | | | | |
| Sales | 11 | 11 | 9 | 11 | 42 | 10 | 10 |
| Adj. EBITDA | -25 | -25 | -25 | -22 | -97 | -24 | -25 |
| Adj. EBIT | -41 | -40 | -36 | -33 | -150 | -35 | -37 |
| Total continuing operations | | | | | | | |
| Sales | 2,021 | 2,008 | 2,035 | 1,934 | 7,998 | 2,045 | 2,020 |
| Adj. EBITDA | 388 | 402 | 388 | 373 | 1,551 | 390 | 371 |
| Adj. EBIT | 254 | 263 | 250 | 222 | 989 | 250 | 222 |
| Discontinued operations | | | | | | | |
| Sales | 271 | 268 | 255 | 218 | 1,012 | 248 | 219 |
| Adj. EBITDA | 36 | 36 | 38 | 23 | 133 | 33 | 31 |
| Adj. EBIT | 25 | 26 | 26 | 9 | 86 | 22 | 20 |
| Total DSM | | | | | | | |
| Sales | 2,292 | 2,276 | 2,290 | 2,152 | 9,010 | 2,293 | 2,239 |
| Adj. EBITDA | 424 | 438 | 426 | 396 | 1,684 | 423 | 402 |
| Adj. EBIT | 279 | 289 | 276 | 231 | 1,075 | 272 | 242 |